Researchers solve failed RSV vax mystery

Researchers have finally figured out why a respiratory syncytial virus vaccine used in 1966 to innoculate children against the infection failed and caused severe respiratory disease. The team, led by Johns Hopkins Children's Center, says antibodies in the vax would not bind to the virus, and thus failed to trigger an immune response. Trials conducted with mice revealed that the vaccine produced a stronger response after being infused with a substance that produced antibodies better equipped to bind to the virus and neutralize it. The results of the initial innoculation attempt effectively halted research on killed-virus vaccines, but these new findings could be the kickstart needed to get that research going again.

"We have found the root cause of the problem, and in doing so we have uncovered clues that will help us design even safer and more effective vaccines in the future," says senior investigator Fernando Polack, M.D., an infectious disease specialist at Hopkins Children's.

- check out the release for more

Suggested Articles

Moderna is entering an important time, its CEO says. And the company is doing so with a new finance chief from Big Biotech.

Not wanting to be left behind in the COVID-19 vaccine race, Europe is stepping up its efforts secure supplies if any immunizations prove effective.

The Trump administration has selected five COVID-19 vaccines for Operation Warp Speed, the NYT reports, with Big Pharma dominating the list.